Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 60, Issue 6, 2006, Pages 751-757

  Nakanishi, Shinsuke ^a,b,c   Kunugi, Hiroshi ^d   Murray, Robin M ^e   Nojima, Seiji ^b   Ogawa, Toyoaki ^g   Takahashi, Toshihiko ^a,f  

^a NAGOYA UNIVERSITY   (Japan)

^b Kitatsushima Hospital   (Japan)

^c AICHI SHUKUTOKU UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f Faculty of Medical Welfare   (Japan)

^g NONE

Author keywords

Atypical antipsychotics; Polypharmacy; Risperidone; Schizophrenia; Switching

Indexed keywords

ANTIPARKINSON AGENT; NEUROLEPTIC AGENT; RISPERIDONE;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; JAPAN; SCHIZOPHRENIA;

ADULT; AGED; ANTI-DYSKINESIA AGENTS; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33750951671     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2006.01591.x     Document Type: Article

References (30)

1. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr. Res. 1999; 35: 51-68.
2. Davis JM, Chen N. Clinical profile of an atypical antipsychotic: risperidone. Schizophr. Bull. 2002; 28: 43-61.
3. Bagnall AM, Jones L, Ginnelly L et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol. Assess. 2003; 7: 1-193.
4. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 2003; 60: 553-564.
5. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. 1999; 25: 201-222.
6. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br. Med. J. 2000; 321: 1371-1376.
7. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl.) 2001; 155: 230-233.
8. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-1589.
9. Lieberman JA, Stroup TS, McEvoy JP et al. Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators: effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005; 353: 1209-1223.
10. Barak Y, Shamir E, Weizman RO. Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study. J. Clin. Psychopharmacol. 2002; 22: 115-120.
11. Desai NM, Huq Z, Martin SD, McDonald G. Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. The Schizophrenia Treatment and Assessment Group. Adv. Ther. 1999; 16: 78-88.
12. Kirov GK, Murray RM, Seth RV, Feeney S. Observations on switching patients with schizophrenia to risperidone treatment. Risperidone Switching Study Group. Acta Psychiatr. Scand. 1997; 95: 439-443.
13. Malla AK, Norman RM, Kotteda V, Zirul S. Switching from therapy with typical antipsychotic agents to risperidone: long-term impact on patient outcome. Clin. Ther. 1999; 21: 806-817.
14. Ritchie CW, Chiu E, Harrigan S et al. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int. J. Geriatr. Psychiatry 2003; 18: 432-440.
15. van Os J, Bosie CA, Lasser RA. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int. Clin. Psychopharmacol. 2004; 19: 229-232.
16. Voruganti L, Cortese L, Owyeumi L et al. Switching from conversational to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr. Res. 2002; 57: 201-208.
17. Mori K, Nagao M, Yamashita H, Morinobu S, Yamawaki S. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004; 28: 659-665.
18. Yamashita H, Mori K, Nagao M, Okamoto Y, Morinobu S, Yamawaki S. Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population. J. Clin. Psychiatry 2004; 65: 1525-1530.
19. Park S, Ross-Degnan D, Adams AS, Sabin J, Kanavos P, Soumerai SB. Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study. Br. J. Psychiatry 2005; 187: 137-142.
20. Chong MY, Tan CH, Fujii S et al. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin. Neurosci. 2004; 58: 61-67.
21. Araki T, Yamasue H, Sumiyoshi T et al. Perospirone in the treatment of schizophrenia: effect on verbal memory organization. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006; 30: 204-208.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DC, 1994.
23. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol. Rep. 1962; 10: 799-812.
24. Inagaki A, Inada T, Fujii Y, Yagi G. Dose equivalence of psychotropic drugs. Part IV. Dose equivalence of orally administered neuroleptics. Jpn J. Clin. Psychopharmacol. 1998; 1: 443-448 (in Japanese).
25. Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. J. Clin. Psychiatry 2004; 65: 1597-1600.
26. Borison RL. Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. The Consensus Study Group on Risperidone Dosing. Clin. Ther. 1996; 18: 592-607.
27. Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch. Gen. Psychiatry 1997; 54: 49-55.
28. Weiden PJ, Aquila R, Dalheim L, Standard JM. Switching antipsychotic medications. J. Clin. Psychiatry 1997; 58 (Suppl. 10): 63-72.
29. Tranter R, Healy D. Neuroleptic discontinuation syndromes. J. Psychopharmacol. 1998; 12: 401-406.
30. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr. Serv. 2003; 54: 55-59.